Characterizing the encapsulation and release of lentivectors and adeno-associated vectors from degradable alginate hydrogels

Justin L. Madrigal, Shahin Shams, Roberta S. Stilhano, Eduardo Silva

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gene therapy using viral vectors has been licensed for clinical use both in the European Union and the United States. Lentivectors (LV) and adeno-associated vectors (AAV) are two promising and FDA approved gene-therapy viral vectors. Many future applications of these vectors will benefit from targeting specific regions of interest within the body. Therefore, building on the early success of these vectors may depend on finding effective delivery systems to localize therapeutic administration. Degradable alginate hydrogels have been tested as appealing delivery vehicles for the controlled delivery of vector payloads. In this study, we compare the ability of two different degradable alginate hydrogel formulations to efficiently deliver LV and AAV. We propose that release rates of viral vectors are dependent on the physical properties of both the hydrogels and vectors. Here, we demonstrate that the initial strength and degradation rate of alginate hydrogels provides levers of control for tuning LV release but do not provide control in the release of AAV. While both alginate formulations used showed sustained release of both LV and AAV, LV release was shown to be dependent on alginate hydrogel degradation, while AAV release was largely governed by diffusive mechanisms. Altogether, this study demonstrates alginate's use as a possible delivery platform for LV and, for the first time, AAV-highlighting the potential of injectable degradable alginate hydrogels to be used as a versatile delivery tool in gene therapy applications.

Original languageEnglish (US)
Pages (from-to)645-656
Number of pages12
JournalBiomaterials Science
Volume7
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Hydrogels
Alginate
Encapsulation
Gene therapy
Hydrogel
alginic acid
Degradation

ASJC Scopus subject areas

  • Biomedical Engineering
  • Materials Science(all)

Cite this

Characterizing the encapsulation and release of lentivectors and adeno-associated vectors from degradable alginate hydrogels. / Madrigal, Justin L.; Shams, Shahin; Stilhano, Roberta S.; Silva, Eduardo.

In: Biomaterials Science, Vol. 7, No. 2, 01.02.2019, p. 645-656.

Research output: Contribution to journalArticle

@article{17d0641268d349f097e478b45490a7e4,
title = "Characterizing the encapsulation and release of lentivectors and adeno-associated vectors from degradable alginate hydrogels",
abstract = "Gene therapy using viral vectors has been licensed for clinical use both in the European Union and the United States. Lentivectors (LV) and adeno-associated vectors (AAV) are two promising and FDA approved gene-therapy viral vectors. Many future applications of these vectors will benefit from targeting specific regions of interest within the body. Therefore, building on the early success of these vectors may depend on finding effective delivery systems to localize therapeutic administration. Degradable alginate hydrogels have been tested as appealing delivery vehicles for the controlled delivery of vector payloads. In this study, we compare the ability of two different degradable alginate hydrogel formulations to efficiently deliver LV and AAV. We propose that release rates of viral vectors are dependent on the physical properties of both the hydrogels and vectors. Here, we demonstrate that the initial strength and degradation rate of alginate hydrogels provides levers of control for tuning LV release but do not provide control in the release of AAV. While both alginate formulations used showed sustained release of both LV and AAV, LV release was shown to be dependent on alginate hydrogel degradation, while AAV release was largely governed by diffusive mechanisms. Altogether, this study demonstrates alginate's use as a possible delivery platform for LV and, for the first time, AAV-highlighting the potential of injectable degradable alginate hydrogels to be used as a versatile delivery tool in gene therapy applications.",
author = "Madrigal, {Justin L.} and Shahin Shams and Stilhano, {Roberta S.} and Eduardo Silva",
year = "2019",
month = "2",
day = "1",
doi = "10.1039/c8bm01218k",
language = "English (US)",
volume = "7",
pages = "645--656",
journal = "Biomaterials Science",
issn = "2047-4830",
publisher = "Royal Society of Chemistry",
number = "2",

}

TY - JOUR

T1 - Characterizing the encapsulation and release of lentivectors and adeno-associated vectors from degradable alginate hydrogels

AU - Madrigal, Justin L.

AU - Shams, Shahin

AU - Stilhano, Roberta S.

AU - Silva, Eduardo

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Gene therapy using viral vectors has been licensed for clinical use both in the European Union and the United States. Lentivectors (LV) and adeno-associated vectors (AAV) are two promising and FDA approved gene-therapy viral vectors. Many future applications of these vectors will benefit from targeting specific regions of interest within the body. Therefore, building on the early success of these vectors may depend on finding effective delivery systems to localize therapeutic administration. Degradable alginate hydrogels have been tested as appealing delivery vehicles for the controlled delivery of vector payloads. In this study, we compare the ability of two different degradable alginate hydrogel formulations to efficiently deliver LV and AAV. We propose that release rates of viral vectors are dependent on the physical properties of both the hydrogels and vectors. Here, we demonstrate that the initial strength and degradation rate of alginate hydrogels provides levers of control for tuning LV release but do not provide control in the release of AAV. While both alginate formulations used showed sustained release of both LV and AAV, LV release was shown to be dependent on alginate hydrogel degradation, while AAV release was largely governed by diffusive mechanisms. Altogether, this study demonstrates alginate's use as a possible delivery platform for LV and, for the first time, AAV-highlighting the potential of injectable degradable alginate hydrogels to be used as a versatile delivery tool in gene therapy applications.

AB - Gene therapy using viral vectors has been licensed for clinical use both in the European Union and the United States. Lentivectors (LV) and adeno-associated vectors (AAV) are two promising and FDA approved gene-therapy viral vectors. Many future applications of these vectors will benefit from targeting specific regions of interest within the body. Therefore, building on the early success of these vectors may depend on finding effective delivery systems to localize therapeutic administration. Degradable alginate hydrogels have been tested as appealing delivery vehicles for the controlled delivery of vector payloads. In this study, we compare the ability of two different degradable alginate hydrogel formulations to efficiently deliver LV and AAV. We propose that release rates of viral vectors are dependent on the physical properties of both the hydrogels and vectors. Here, we demonstrate that the initial strength and degradation rate of alginate hydrogels provides levers of control for tuning LV release but do not provide control in the release of AAV. While both alginate formulations used showed sustained release of both LV and AAV, LV release was shown to be dependent on alginate hydrogel degradation, while AAV release was largely governed by diffusive mechanisms. Altogether, this study demonstrates alginate's use as a possible delivery platform for LV and, for the first time, AAV-highlighting the potential of injectable degradable alginate hydrogels to be used as a versatile delivery tool in gene therapy applications.

UR - http://www.scopus.com/inward/record.url?scp=85060655173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060655173&partnerID=8YFLogxK

U2 - 10.1039/c8bm01218k

DO - 10.1039/c8bm01218k

M3 - Article

C2 - 30534722

AN - SCOPUS:85060655173

VL - 7

SP - 645

EP - 656

JO - Biomaterials Science

JF - Biomaterials Science

SN - 2047-4830

IS - 2

ER -